

29 JUN 2010



Safeguarding public health

0107 NOV 07

Dr H Markus
ST GEORGE'S UNIVERSITY OF LONDON
CRANMER TERRACE
LONDON
SW17 0RE
UNITED KINGDOM

28/06/2010

Dear Dr H Markus

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	16745/0205/001-0018
Eudract Number:	2006-002827-18
Product:	Aspirin
Protocol number:	RBF0032
Substantial Amendment Code Number:	04/Q0803/215 Substantial Amendment No. 17, 18th May 2010

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 27/05/2010.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**